Acrivon Therapeutics Q2 net loss narrows as costs decline
ACRV•Outlook and key figures
Acrivon expects cash and investments to fund operations into the fourth quarter of 2027.
| Metric | Actual |
|---|---|
| Q2 Net Loss | $17.96 mln |
| Q2 Income From Operations | -$18.67 mln |
| Q2 Loss Per Basic Share | $0.43 |
| Q2 Operating Expenses | $18.67 mln |
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell". The average consensus recommendation for the biotechnology & medical research peer group is "buy".
Wall Street's median 12-month price target for Acrivon Therapeutics, Inc. is $10.50, about 506.9% above its August 11 closing price of $1.73.
Quarterly results and cost changes
- US biopharma firm's Q2 net loss narrowed from prior year
- Operating expenses fell, mainly due to lower R&D and employee-related costs
- Company ended Q2 with $90 mln in cash and investments, funding expected into Q4 2027
Acrivon Therapeutics said its Q2 net loss narrowed from a year earlier as operating expenses declined, mainly because of lower research and development spending and reduced employee-related costs.
The company said research and development expenses fell mainly due to two ACR-368 milestones in 2025 that did not recur in 2026 and the timing of other program progressions. General and administrative expenses also declined due to reduced employee-related expenses, including stock-based compensation.
